Evidence map›Paper›PMID 29204155›Full record

ReviewGastroenterology research and practice2017

A Meta-Analysis of Adalimumab for Fistula in Crohn's Disease.

Yin-Mei Fu, Ming Chen, Ai-Jun Liao

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterology research and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Perianal fistulizing Crohn's disease: Clinical practice update from Colitis and Crohn's Foundation (India).Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026
    Guideline
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Maneuvering Clinical Pathways for Crohn's Disease.Current gastroenterology reports · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Yin-Mei FuDepartment of Gastroenterology and Hepatology, First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China.
Ming ChenDepartment of Gastroenterology and Hepatology, First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China.
Ai-Jun LiaoDepartment of Gastroenterology and Hepatology, First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China.ORCID 0000-0001-7631-6157
First Affiliated Hospital of University of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to evaluate the therapeutic value of adalimumab (ADA) for fistula in Crohn's disease (CD).

methodsA computerized search of electronic databases, including PubMed, Web of Science, Embase, Google scholar, and the Cochrane Library from 2000 to October 2016, was performed. Randomized controlled trials (rcts) or nonrandomized controlled trials (n-rcts) were included in this article to evaluate the role of ADA in the management of fistula in CD. The methodological index for nonrandomized studies (MINORS evaluation tools) was used to assess the quality of every study.

resultOverall, seven studies and 379 patients comforted to the inclusion criteria of this meta-analysis. The result showed that 36% (95% CI: 0.31-0.41) of patients with complete fistula closure and 31% (95% CI: 0.031-0.61) of patients with partial response were received in CD with ADA treatment.

conclusionWe concluded that ADA is effective and safe for the treatment of fistula in CD according to current evidence.

Identifiers

PMID29204155
PMCPMC5674503
OpenAlexW2765292279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.